ImmunoGen , Inc.

Industry:	Pharmaceuticals, Drug Manufacturing & Research, Biotechnology
Ranking:	Russell 3000
Revenues:	$38.2 Million
Employees:	213

Description

ImmunoGen, Inc. is focused on the development of antibody-based anticancer therapeutics. The Company’s Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to cancer cells. The antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen and the cytotoxic agent serves to kill the cancer cell. Its TAP technology is designed to enable the creation of anticancer products. The Company’s TAP technology can be used with antibodies that have anticancer activity of their own to create compounds with enhanced anticancer activity. In addition, its TAP technology can be used with antibodies that lack anticancer activity. The Company developed its cell-killing agents specifically for antibody-directed delivery to cancer targets. The Company has developed alternative maytansinoid cell-killing agents (such as DM1 and DM4) and linkers.
(Source: 10-K)

Products & Services

targeted anticancer biopharmaceuticals, targeted anticancer therapeutics, clinical materials, targeted anticancer therapies

Find More Jobs

Job Openings

Scientist - Process Development Waltham , MA

News Archive

ImmunoGen's Stock Dives On Bad News From GSK, Genentech. BIOWORLD Today; 11/4/2009 Senior Staff Writer ImmunoGen Inc. made public Monday deflating...Those combined announcements drove ImmunoGen's stock (NASDAQ:IMGN) down...close at $2.15. Mitchel Sayare, ImmunoGen's chairman and CEO, said GlaxoSmithKline... ...more

ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders. Cancer Weekly; 11/24/2009 ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology...Chairman of the Board, replacing former ImmunoGen CEO Mitchel Sayare, Ph.D., in this...on the Board as a director (see also ImmunoGen, Inc.). "We believe now is an appropriate... ...more

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology. Business Wire; 11/19/2009 WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology...licensed the exclusive right to use ImmunoGen's TAP technology for another undisclosed...grants Amgen certain rights to test ImmunoGen's maytansinoid TAP technology and... ...more